Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Wenjiao Xia, Xin Qi, Mingfeng Li, Yu Wu, Lulu Sun, Xinglong Fan, Yuan Yuan & Jing Li. (2021) Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner. OncoImmunology 10:1.
Read now
Read now
Jon Røikjær Henriksen, Line Nederby, Frede Donskov, Marianne Waldstrøm, Parvin Adimi, Anders Jakobsen & Karina Dahl Steffensen. (2020) Blood natural killer cells during treatment in recurrent ovarian cancer. Acta Oncologica 59:11, pages 1365-1373.
Read now
Read now
Jon Røikjaer Henriksen, Frede Donskov, Marianne Waldstrøm, Anders Jakobsen, Mette Hjortkjaer, Christina Braad Petersen & Karina Dahl Steffensen. (2020) Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. Acta Oncologica 59:6, pages 652-659.
Read now
Read now
Articles from other publishers (56)
Pedram Motallebnejad, Anne Kantardjieff, Frank Cichocki, Samira M. Azarin & Wei-Shou Hu. (2023) Process engineering of natural killer cell-based immunotherapy. Trends in Biotechnology 41:10, pages 1314-1326.
Crossref
Crossref
Takanori Kitamura. (2023) Tumour-associated macrophages as a potential target to improve natural killer cell-based immunotherapies. Essays in Biochemistry 67:6, pages 1003-1014.
Crossref
Crossref
Yen Hoon Luah, Tongjin Wu & Lih Feng Cheow. (2023) Identification, sorting and profiling of functional killer cells via the capture of fluorescent target-cell lysate. Nature Biomedical Engineering.
Crossref
Crossref
Mingfeng Li, Aotong Zhang, Yanqing Wang, Jiaxin Chen, Xin Qi, Yuanren Ma, Chunxiao Huang, Ying Xiong, Xiaomin Zhang, Wenjiao Xia, Dehai Li, Yankai Liu, Zhicheng Zuo & Jing Li. (2023) Cycloartenyl ferulate improves natural killer (NK) cell immunity against cancer by binding to IFNγ receptor 1. Journal of Biological Chemistry 299:8, pages 104990.
Crossref
Crossref
Tahereh Hojjatipour, Zahra Sharifzadeh, Amirhosein Maali & Mehdi Azad. (2023) Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells. Human Cell 36:6, pages 1843-1864.
Crossref
Crossref
Md Faqrul Hasan, Tayler J. Croom-Perez, Jeremiah L. Oyer, Thomas A. Dieffenthaller, Liza D. Robles-Carrillo, Jonathan E. Eloriaga, Sanjana Kumar, Brendan W. Andersen & Alicja J. Copik. (2023) TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies. Cancers 15:10, pages 2712.
Crossref
Crossref
Dok Hyun Yoon, Youngil Koh, Miyoung Jung, Jeong-Eun Kwak, Eui-Cheol Shin, Yu Kyeong Hwang & Won Seog Kim. (2023) Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma. Transplantation and Cellular Therapy 29:4, pages 253.e1-253.e9.
Crossref
Crossref
Kassandra M. Coyle, Lindsey G. Hawke & Mark L. Ormiston. (2023) Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics. Cancers 15:6, pages 1743.
Crossref
Crossref
Neda Minaei, Roya Ramezankhani, Atena Tamimi, Abbas Piryaei, Ali Zarrabi, Amir Reza Aref, Ebrahim Mostafavi & Massoud Vosough. (2023) Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. European Journal of Cell Biology 102:1, pages 151284.
Crossref
Crossref
Alireza Zafarani, Mahsa Taghavi-Farahabadi, Mohammad Hossein Razizadeh, Mohammad Reza Amirzargar, Mansoure Mansouri & Mohammad Mahmoudi. (2022) The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia. Stem Cell Reviews and Reports 19:1, pages 26-45.
Crossref
Crossref
Tatsiana V. Shman, Katsiaryna P. Vashkevich, Alexandr A. Migas, Mikhail A. Matveyenka, Yauheni A. Lasiukov, Nastassia S. Mukhametshyna, Katsiaryna I. Horbach & Olga V. Aleinikova. (2022) Phenotypic and functional characterisation of locally produced natural killer cells ex vivo expanded with the K562-41BBL-mbIL21 cell line. Clinical and Experimental Medicine 23:6, pages 2551-2560.
Crossref
Crossref
Seung Kwon Koh, Jeehun Park, Seong-Eun Kim, Yuree Lim, Minh-Trang Thi Phan, Jinho Kim, Ilwoong Hwang, Yong-Oon Ahn, Sue Shin, Junsang Doh & Duck Cho. (2022) Natural Killer Cell Expansion and Cytotoxicity Differ Depending on the Culture Medium Used. Annals of Laboratory Medicine 42:6, pages 638-649.
Crossref
Crossref
Le Tong, Carlos Jiménez-Cortegana, Apple H.M. Tay, Stina Wickström, Lorenzo Galluzzi & Andreas Lundqvist. (2022) NK cells and solid tumors: therapeutic potential and persisting obstacles. Molecular Cancer 21:1.
Crossref
Crossref
Sheena Pinto, Jens Pahl, Arndt Schottelius, Paul J. Carter & Joachim Koch. (2022) Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. Trends in Immunology 43:11, pages 932-946.
Crossref
Crossref
G. M. Yusubalieva, E. B. Dashinimaev, A. A. Gorchakov, S. V. Kulemzin, O. A. Brovkina, A. A. Kalinkin, A. G. Vinokurov, M. V. Shirmanova, A. V. Taranin & V. P. Baklaushev. (2022) Enhanced Natural Killers with CISH and B2M Gene Knockouts Reveal Increased Cytotoxicity in Glioblastoma Primary Cultures. Molecular Biology 56:5, pages 770-779.
Crossref
Crossref
Sang-Jin Park, Hae-Jin Yoon, Eun-Young Gu, Byoung-Seok Lee, Yongman Kim, Jaeseob Jung, Jinmoon Kim & Kyoung-Sik Moon. (2022) A general toxicity and biodistribution study of human natural killer cells by single or repeated intravenous dose in severe combined immune deficient mice. Toxicological Research 38:4, pages 545-555.
Crossref
Crossref
Laura Kiekens, Wouter Van Loocke, Sylvie Taveirne, Sigrid Wahlen, Eva Persyn, Els Van Ammel, Zenzi De Vos, Patrick Matthys, Filip Van Nieuwerburgh, Tom Taghon, Pieter Van Vlierberghe, Bart Vandekerckhove & Georges Leclercq. (2021) T-BET and EOMES Accelerate and Enhance Functional Differentiation of Human Natural Killer Cells. Frontiers in Immunology 12.
Crossref
Crossref
E Hui Clarissa Lee, Darren Chen Pei Wong & Jeak Ling Ding. (2021) NK Cells in a Tug-of-War With Cancer: The Roles of Transcription Factors and Cytoskeleton. Frontiers in Immunology 12.
Crossref
Crossref
Alicia A. Gingrich, Taylor E. Reiter, Sean J. Judge, Daniel York, Mio Yanagisawa, Aryana Razmara, Ian Sturgill, Ugur Nur Basmaci, Rachel V. Brady, Kevin Stoffel, William J. Murphy, Robert B. Rebhun, C. Titus Brown & Robert J. Canter. (2021) Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target. Frontiers in Immunology 12.
Crossref
Crossref
Brian J Kwee & Kyung E Sung. (2021) Engineering microenvironments for manufacturing therapeutic cells. Experimental Biology and Medicine 246:16, pages 1845-1856.
Crossref
Crossref
Valentina Cazzetta, Sara Franzese, Claudia Carenza, Silvia Della Bella, Joanna Mikulak & Domenico Mavilio. (2021) Natural Killer–Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy. Cancers 13:9, pages 2184.
Crossref
Crossref
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, Gerard M. J. Bos & Wilfred T. V. Germeraad. (2021) Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Rasa Islam, Aleta Pupovac, Vera Evtimov, Nicholas Boyd, Runzhe Shu, Richard Boyd & Alan Trounson. (2021) Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy. Cells 10:5, pages 1058.
Crossref
Crossref
Tianlin Zhou, Jinrong Peng, Ying Hao, Kun Shi, Kai Zhou, Yun Yang, Chengli Yang, Xinlong He, Xinmian Chen & Zhiyong Qian. (2021) The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure. Bioactive Materials 6:3, pages 697-711.
Crossref
Crossref
Karen Slattery, Elena Woods, Vanessa Zaiatz-Bittencourt, Sam Marks, Sonya Chew, Michael Conroy, Caitriona Goggin, Colm MacEochagain, John Kennedy, Sophie Lucas, David K Finlay & Clair M Gardiner. (2021) TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer. Journal for ImmunoTherapy of Cancer 9:2, pages e002044.
Crossref
Crossref
Harsimrat Kaur Birdi, Anna Jirovec, Serena Cortés-Kaplan, Joel Werier, Carolyn Nessim, Jean-Simon Diallo & Michele Ardolino. (2021) Immunotherapy for sarcomas: new frontiers and unveiled opportunities. Journal for ImmunoTherapy of Cancer 9:2, pages e001580.
Crossref
Crossref
Anna Makowska, Selina Meier, Lian Shen, Pierre Busson, Valentin Baloche & Udo Kontny. (2020) Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1. Cancer Immunology, Immunotherapy 70:2, pages 323-336.
Crossref
Crossref
Zhengtian Li, Rong Zhao, Wenkang Yang, Chan Li, Jun Huang, Zhenpei Wen, Gang Du & Lingling Jiang. (2021) PLCG2 as a potential indicator of tumor microenvironment remodeling in soft tissue sarcoma. Medicine 100:11, pages e25008.
Crossref
Crossref
Min Liu, Yuan Meng, Leisheng Zhang, Zhongchao Han & Xiaoming Feng. (2021) High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18. Biochemical and Biophysical Research Communications 534, pages 149-156.
Crossref
Crossref
Sean J Judge, Morgan A Darrow, Steve W Thorpe, Alicia A Gingrich, Edmond F O'Donnell, Alyssa R Bellini, Ian R Sturgill, Logan V Vick, Cordelia Dunai, Kevin M Stoffel, Yue Lyu, Shuai Chen, May Cho, Robert B Rebhun, Arta M Monjazeb, William J Murphy & Robert J Canter. (2020) Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. Journal for ImmunoTherapy of Cancer 8:2, pages e001355.
Crossref
Crossref
Ji Ye Lim & Xiang-Dong Wang. (2020) Mechanistic understanding of β-cryptoxanthin and lycopene in cancer prevention in animal models. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1865:11, pages 158652.
Crossref
Crossref
Yuan-yuan Jin, Wen-zhuo YangSen Zou, Zheng-yang Sun, Chun-tao Wu & Zhao-yong Yang. (2020) Chemoradiotherapy combined with NK cell transfer in a patient with recurrent and metastatic nasopharyngeal carcinoma inducing long-term tumor control. Medicine 99:43, pages e22785.
Crossref
Crossref
Hao Yang, Hongyan Zhou, Zhenglan Huang, Kun Tao, Ningshu Huang, Zhi Peng & Wenli Feng. (2020) Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides. Cancer Letters 482, pages 44-55.
Crossref
Crossref
Takahiro Domoto, Masahiro Uehara, Dilireba Bolidong & Toshinari Minamoto. (2020) Glycogen Synthase Kinase 3β in Cancer Biology and Treatment. Cells 9:6, pages 1388.
Crossref
Crossref
Ying Gong, Roel G.J. Klein Wolterink, Ian Janssen, Arjan J. Groot, Gerard M.J. Bos & Wilfred T.V. Germeraad. (2020) Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor. Molecular Therapy - Methods & Clinical Development 17, pages 634-646.
Crossref
Crossref
C. Quintarelli, S. Sivori, S. Caruso, S. Carlomagno, M. Falco, I. Boffa, D. Orlando, M. Guercio, Z. Abbaszadeh, M. Sinibaldi, S. Di Cecca, A. Camera, B. Cembrola, A. Pitisci, M. Andreani, L. Vinti, S. Gattari, F. Del Bufalo, M. Algeri, G. Li Pira, A. Moseley, B. De Angelis, L. Moretta & F. Locatelli. (2019) Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia. Leukemia 34:4, pages 1102-1115.
Crossref
Crossref
Da-Un Jeong, Jeong Su Byeon, Na-Yeon Gu, Moonhee Jung, Eun Hee Kim, Hyung-Seok Kim, In-Soo Cho, Jae-Young Song, Bang-Hun Hyun & Jienny Lee. (2020) Cytotoxicity of natural killer cells on canine mammary carcinoma cells. Korean Journal of Veterinary Research 60:1, pages 25-32.
Crossref
Crossref
V. G. Subrakova, S. V. Kulemzin, T. N. Belovezhets, A. N. Chikaev, N. A. Chikaev, O. A. Koval, A. A. Gorchakov & A. V. Taranin. (2020) <i>shp-2</i> gene knockout upregulates CAR-driven cytotoxicity of YT NK cells. Vavilov Journal of Genetics and Breeding 24:1, pages 80-86.
Crossref
Crossref
Aviad Ben-Shmuel, Guy Biber & Mira Barda-Saad. (2020) Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?. Frontiers in Immunology 11.
Crossref
Crossref
Muhammad Khan, Sumbal Arooj & Hua Wang. (2020) NK Cell-Based Immune Checkpoint Inhibition. Frontiers in Immunology 11.
Crossref
Crossref
Sean J. Judge, William J. Murphy & Robert J. Canter. (2020) Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence. Frontiers in Cellular and Infection Microbiology 10.
Crossref
Crossref
Daham Kim, Namki Hong, Yonggeun Cho, Sang-Guk Lee & Yumie Rhee. (2020) Heterophile antibody interference associated with natural killer cell therapy. Endocrine Journal 67:12, pages 1187-1192.
Crossref
Crossref
Leslie Elsner & Ralf Dressel. 2020. Tumor Immunology and Immunotherapy – Cellular Methods Part A. Tumor Immunology and Immunotherapy – Cellular Methods Part A
497
512
.
Ana Santos Cravo & Randall Mrsny. 2020. Biomaterials for Cancer Therapeutics. Biomaterials for Cancer Therapeutics
1
22
.
Liangliang Xu, Weiping Lin, Longping Wen & Gang Li. (2019) Lgr5 in cancer biology: functional identification of Lgr5 in cancer progression and potential opportunities for novel therapy. Stem Cell Research & Therapy 10:1.
Crossref
Crossref
Allison B. Powell, Sridevi Yadavilli, Devin Saunders, Stacey Van Pelt, Elizabeth Chorvinsky, Rachel A. Burga, Shuroug Albihani, Patrick J. Hanley, Zhenhua Xu, Yanxin Pei, Eric S. Yvon, Eugene I. Hwang, Catherine M. Bollard, Javad Nazarian & Conrad Russell Y. Cruz. (2019) Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization. Journal of Translational Medicine 17:1.
Crossref
Crossref
Alicia A. Gingrich, Jaime F. Modiano & Robert J. Canter. (2019) Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy. Journal of Clinical Medicine 8:11, pages 1802.
Crossref
Crossref
Sooyeon Oh, Joo-Ho Lee, KyuBum Kwack & Sang-Woon Choi. (2019) Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors. Cancers 11:10, pages 1534.
Crossref
Crossref
Faezeh Ghaemdoust, Mahsa Keshavarz-Fathi & Nima Rezaei. (2019) Natural killer cells and cancer therapy, what we know and where we are going. Immunotherapy 11:14, pages 1231-1251.
Crossref
Crossref
Gonzalez-Rodriguez, Villa-Álvarez, Sordo-Bahamonde, Lorenzo-Herrero & Gonzalez. (2019) NK Cells in the Treatment of Hematological Malignancies. Journal of Clinical Medicine 8:10, pages 1557.
Crossref
Crossref
Sizhe Liu, Payal Dhar & Jennifer D. Wu. (2019) NK Cell Plasticity in Cancer. Journal of Clinical Medicine 8:9, pages 1492.
Crossref
Crossref
Dan Wu, Yunru Yu, Cheng Zhao, Xin Shou, Yun Piao, Xin Zhao, Yuanjin Zhao & Shuqi Wang. (2019) NK-Cell-Encapsulated Porous Microspheres via Microfluidic Electrospray for Tumor Immunotherapy. ACS Applied Materials & Interfaces 11:37, pages 33716-33724.
Crossref
Crossref
Marcelo J. Sakiyama, Ingrid Espinoza, Amit Reddy, Flavia de Carlo, Avinash Kumar, Anait S. Levenson, Sejong Bae, Xinchun Zhou, Pier Paolo Claudio, Jack Lewin, Varsha Manucha, Charles R. Pound, Srinivasan Vijayakumar & Christian R. Gomez. (2019) Race-associated expression of MHC class I polypeptide-related sequence A (MICA) in prostate cancer. Experimental and Molecular Pathology 108, pages 173-182.
Crossref
Crossref
Upkar S. Gill & Lucy Golden-Mason. (2019) HCMV jogs the ‘memory’ of NK cells in HBV. Journal of Hepatology 70:3, pages 343-345.
Crossref
Crossref
Janneke Hoogstad-van Evert, Ruud Bekkers, Nelleke Ottevanger, Nicolaas Schaap, Willemijn HoboJoop H. JansenLeon Massuger & Harry Dolstra. (2019) Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study). Medicine 98:5, pages e14290.
Crossref
Crossref
Clara Di Vito, Joanna Mikulak, Elisa Zaghi, Silvia Pesce, Emanuela Marcenaro & Domenico Mavilio. (2019) NK cells to cure cancer. Seminars in Immunology 41, pages 101272.
Crossref
Crossref